Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday formalized multiple commercial Group Purchasing Organization (GPO) agreements for Rezenopy (naloxone HCl) Nasal Spray 10 mg.
Rezenopy, an opioid antagonist, received FDA approval in April 2024 for the emergency treatment of known or suspected opioid overdose.
Scienture secured exclusive U.S. commercialization rights to Rezenopy from Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025.
Expanded Institutional Footprint For Scienture
The agreement provides access to over 5000 healthcare institutions, including hospitals, clinics, and nursing homes, representing potential penetration into roughly 60% of the U.S. institutional market.
The deal also establishes a broad footprint across first responders, EMS providers, and rehabilitation centers.
“These GPO agreements represent a significant step forward in the commercial expansion of Rezenopy,” commented Narasimhan Mani, President and co-CEO …
This post was originally published here
